PM
62
-2
YUM
47
3
WM
79
3
PVH
62
5
AA
48
-12
NWL
53
3
NSC
60
3
BBY
46
10
PFE
23
7
MAT
46
12
FDX
43
3
FLR
58
3
TXT
55
3
RHI
59
2
KMB
39
2
ADBE
49
3
DTE
56
2
XRX
44
3
RIG
60
2
LYB
39
2
PM
62
-2
YUM
47
3
WM
79
3
PVH
62
5
AA
48
-12
NWL
53
3
NSC
60
3
BBY
46
10
PFE
23
7
MAT
46
12
FDX
43
3
FLR
58
3
TXT
55
3
RHI
59
2
KMB
39
2
ADBE
49
3
DTE
56
2
XRX
44
3
RIG
60
2
LYB
39
2
Financhill
Back

Molecular Partners AG 10K Form

Sell
21

MOLN
Molecular Partners AG

Last Price:
5.31
Seasonality Move:
43.69%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MOLN News And Ratings

See the #1 stock for the next 7 days that we like better than MOLN

MOLN Financial Statistics

Sales & Book Value

Annual Sales: $7.84M
Cash Flow: $-17.34M
Price / Cash Flow: 0
Annual Sales: $4.97
Price / Book: 1.18

Profitability

EPS (TTM): -2.14130
Net Income (TTM): $-70.92M
Gross Margin: --
Return on Equity: -37.36%
Return on Assets: -33.67%

Molecular Partners AG Earnings Forecast

Key Molecular Partners AG Financial Ratios

  • The Research & Development expenses have been 693.15% of Revenue.
  • The Interest Expense is -0.05% of Operating Income.
  • The Net Earning history of MOLN is -880.71% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 4 years.

Molecular Partners AG Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: MOLN
Website: molecularpartners.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 14.33
Quick Ratio: 14.08

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

MOLN Technical Analysis vs Fundamental Analysis

Sell
21
Molecular Partners AG (MOLN) is a Sell

Is Molecular Partners AG a Buy or a Sell?